VENTANA PD-L1 (SP142) Assay

PD-L1 predictive assay | Guiding immunotherapy

The VENTANA PD-L1 (SP142) Assay identifies patients most likely to benefit from TECENTRIQ®
Health Canada approved.

Using the right test to determine PD-L1 status for immunotherapy options is important. The VENTANA PD-L1 (SP142) Assay* is the first and only Health Canada approved test predictive for TECENTRIQ® in urothelial carcinoma (UC) patients. This novel assay is also the first to evaluate patient’s PD-L1 expression using immune cell staining and scoring within the tumor microenvironment, providing you with information that can guide immunotherapy decisions.

The VENTANA PD-L1 (SP142) Assay:
  • Health Canada approved to assess UC patient treatment benefit from to TECENTRIQ®
  • Informative for the clinician of a patient’s potential objective response rate (ORR)
  • Optimized to enhance visual contrast of immune cell staining within the tumor microenvironment
  • Stains PD-L1 in both tumor cells (TC) and tumor-infiltrating immune cells (IC)

*Only available on the VENTANA BenchMark ULTRA Instrument.


This Web site contains information on products which is targeted to a wide range of audiences in Canada and could contain product details or information otherwise not accessible or valid in another country.
Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage outside Canada